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Objectives: A considerable portion of the adult population has received and/or is 
receiving treatment with antiresorptive drugs (ARDs). It is thus relevant to assess 
possible side effects of ARD intake in connection to various aspects of implant ther‐
apy. The aim of this study was to answer the focused question “In patients with sys‐
temic intake of ARDs, what is the outcome and complication rate of implant therapy 
including associated bone grafting procedures comparing to patients without sys‐
temic intake of ARDs?”
Materials and Methods: Original studies fulfilled predefined inclusion criteria (e.g., 
case series, cohort studies, case–control studies, and controlled and/or randomized 
controlled clinical trials; retro‐ or prospective design; and ≥10 patients with systemic 
intake of ARDs). Various patient‐, medication‐, and intervention‐related parameters 
[i.e., implant loss, grafting procedure complication/failure, peri‐implant marginal 
bone levels/loss, medication‐related osteonecrosis of the jaws (MRONJ), and peri‐
implantitis] were extracted, and meta‐analyses and quality assessment were 
performed.
Results: Twenty‐four studies with bisphosphonate (BP) intake (mainly low dose for 
osteoporosis treatment) and seven studies on hormone replacement therapy (HRT), 
including ≥10 patients, and controls not taking the medication were identified. 
Furthermore, seven studies on MRONJ associated with implants were included. 
Meta‐analyses based on four studies reporting on patient level and eight studies re‐
porting on implant level showed no significant differences in terms of implant loss 
between patients on BPs (mainly low dose for osteoporosis treatment) and controls. 
Furthermore, low‐dose BP intake did not compromise peri‐implant marginal bone 
levels. Based on two studies, no negative effect of HRT was observed on the implant 
level, while HRT appeared to exert a marginally significant negative effect regarding 
implant survival on the patient level and regarding peri‐implant marginal bone levels. 
Based on six studies reporting single‐patient data, MRONJ in patients on BP for os‐
teoporosis appeared in 70% of the cases >36 months after start of drug intake, while 
in patients with cancer, MRONJ appeared in 64% of the cases ≤36 months after first 
BP intake.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2018 The Authors. Clinical Oral Implants Research Published by John Wiley & Sons Ltd.
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1  | INTRODUC TION
Drugs counteracting bone resorption, coined antiresorptive drugs 
(ARDs), interfere with bone metabolism with the aim to decrease abnor‐
mal bone remodeling and/or increased bone resorption. ARDs, despite 
differences in their mechanisms of action, in general, decrease bone 
remodeling and resorption by inhibiting differentiation and normal 
function of osteoclasts (OCLs), and/or increase their apoptosis (Baron, 
Ferrari, & Russell, 2011). ARDs are thus most commonly/primarily used 
in the treatment of osteoporosis and primary and metastatic skeletal 
malignancies, to prevent events such as fractures, and limit pain and 
metastatic spread; ARDs are also used in less frequent diseases such as 
Paget’s disease of the bone and osteogenesis imperfecta.
The most widely known ARDs are the bisphosphonates (BPs), a 
group of drugs introduced >30 years ago. Currently used nitrogen‐
containing BPs (e.g., alendronate, risedronate, ibandronate, pamid‐
ronate, and zoledronate) bind readily to hydroxylapatite and are 
deposited into the bone. They exert antiresorptive action by inhib‐
iting OCL progenitor development and disturbing OCL function (i.e., 
recruitment, adhesion, and activity), while also reducing OCL lifes‐
pan; a direct inhibiting effect on osteoblasts has also been suggested 
(Baron et al., 2011; Stepan, Alenfeld, Boivin, Feyen, & Lakatos, 2003). 
The administration route influences skeletal uptake of BPs and thus 
indirectly the dose; specifically, intravenously (iv) administered BPs 
(e.g., pamidronate and zoledronate) are bound in very large quan‐
tities and are used mainly in the management of malignancies and 
Paget’s disease of bone, and only in rather limited extent for oste‐
oporosis treatment, while orally administered BPs (e.g., alendronate 
and risedronate) are bound in significantly smaller quantities (<1% of 
orally administered BPs is absorbed from the gastrointestinal tract) 
and are predominantly used in the treatment of osteoporosis and 
rarely, in some types of cancers, for the prevention of secondary 
osteoporosis. Relatively recently, another treatment option for os‐
teoporosis has been oral administration of strontium ranelate (SrR), 
which—although the exact mechanisms of action are not completely 
understood—seems to interfere with bone metabolism by decreasing 
OCL progenitor differentiation and OCL activity, and increasing their 
apoptosis, while it also increases osteoblast (OB) progenitor differ‐
entiation and OB activity and survival (Bonnelye, Chabadel, Saltel, & 
Jurdic, 2008; Buehler, Chappuis, Saffar, Tsouderos, & Vignery, 2001). 
Currently, SrR use appears to be gradually abandoned, because it 
has been suspected of having a higher risk of adverse cardiovascular 
events (European Medicines Agency, 2013), although a very recent 
study did not confirm this (Martín‐Merino et al., 2018).
Treatment of osteopenia and osteoporosis has also been pursued 
by targeting estrogen deficiency, which is a major cause for these 
conditions during menopause. Estrogen deficiency upregulates sev‐
eral cytokines, including receptor activator of nuclear factor kappa B 
ligand (RANKL), while it downregulates others, including osteoprote‐
gerin (OPG). Thus, hormone replacement therapy (HRT) with direct 
estrogen supplementation exerts its antiresorptive effect predomi‐
nantly through regulating RANKL production by the OB and thereby 
influencing OCL. Additionally, estrogen has a direct effect on OCL pre‐
cursors by reducing their responsiveness to RANKL and also on OB 
by stimulating their proliferation and reducing their apoptosis (Stepan 
et al., 2003). HRT with estrogen is currently prescribed in rather lim‐
ited extent, mostly for the management of climacteric symptoms, due 
to the risk of adverse cardiovascular events (Wong et al., 2017). A 
somehow similar treatment approach is the administration of selective 
estrogen receptors modulators (SERMs; e.g., raloxifene and bazedoxi‐
fene), which are drugs acting on the estrogen receptor and having a se‐
lective estrogenic effect on bone tissue, or by administering calcitonin 
that binds to its OCL receptor and interferes with normal cell function, 
including secretion of proteolytic enzymes (Carter & Schipani, 2006).
More recently, a new generation of “biological” ARDs has been 
introduced based on monoclonal antibodies targeting various mech‐
anisms relevant to bone remodeling. The most widely used is denos‐
umab (Reginster et al., 2014), which is a fully humanized antibody of 
Conclusion: Low‐dose oral BP intake for osteoporosis treatment, in general, does not 
compromise implant therapy, that is, patients on ARDs do not lose more implants nor 
get more implant‐related complications/failures comparing to implant patients with‐
out BP intake. There is almost no information available on the possible effect on im‐
plant therapy of high‐dose BPs or other widely used ARDs (e.g., denosumab), or on 
the success or safety of bone grafting procedures. Patients with high‐dose ARD in‐
take for management of malignancies, patients on oral BP over a longer period of 
time, and patients with comorbidities should be considered as high‐risk patients for 
MRONJ.
K E Y W O R D S
antiresorptive drugs, bisphosphonates, dental implants, hormone replacement therapy, 
medication‐related osteonecrosis of the jaws, systematic review
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RANKL. Denosumab exerts its antiresorptive effect by blocking the 
binding of RANKL to RANK, and thus interfering with OCL differen‐
tiation, and, in contrast to BPs, does not bind to bone. Denosumab 
is administered subcutaneously (sc) and in various intervals depend‐
ing on its treatment purpose (i.e., for osteoporosis or malignancies) 
(Reginster et al., 2014). Recent market analyses estimated about 
>40% of current osteoporosis treatments are with denosumab 
(Global Osteoporosis Market & Drugs Analysis 2010–2015, 2011). 
Similar approaches regard the use of cathepsin K (CatK) inhibitor 
(odanacatib) and c‐Src kinase inhibitor (saracatinib) or the use of an 
antisclerostin monoclonal antibody (romosozumab).
In perspective, current estimates indicate that about 15% of the 
population >50 years of age in the European Union (EU) has osteo‐
porosis; this translates into ca. 23.5 million women and 6.0 million 
men in the year 2015 and, when considering demographic trends, 
into ca. 27.5 million women and 7.0 million men in the year 2025 
(Hernlund et al., 2013). Despite the fact that consumption may 
vary significantly among countries/regions, due to differences in 
prescription rates depending on the regulatory framework and/or 
treatment uptake, as well as the appearance of newer ARDs (e.g., 
denosumab), BPs appear still the most prevalent drugs for osteo‐
porosis treatment within the EU. In this context, even if patients 
with osteoporosis are currently not treated with BPs, the majority 
has most likely received BPs in the past; based on market shares 
(Hernlund et al., 2013), it was estimated that oral BPs covered 
about 70% of osteoporosis treatment in 2010. Thus, as a consider‐
able number of patients attending a dental clinic are suffering from 
osteoporosis, and a major portion of them has received and/or is 
receiving treatment with ARDs, it is important to consider possible 
side effects; specifically, dentoalveolar procedures, including den‐
tal implant and bone augmentation therapies, might be affected 
by drugs interfering with bone remodeling. In particular, a specific 
side effect of ARDs associated with dentoalveolar procedures is 
osteonecrosis of the jaws; this condition, recognized already for 
more than a decade ago regarding BPs, is characterized by exposed 
bone or bone that can be probed through an intra‐ or extraoral fis‐
tula in the maxillofacial region and that has persisted for >8 weeks. 
Currently, the condition is termed “medication‐related osteone‐
crosis of the jaws” (MRONJ), to reflect the fact that similar lesions 
can be associated with several ARDs and not exclusively with BPs.
Various available reviews on this topic generally agree that still 
relatively little information is available in regard to possible effects 
of ARDs on relevant aspects of implant therapy, such as implant 
failure rate, marginal bone loss, and MRONJ development. Further, 
there is no comprehensive review regarding the possible effect of 
ARDs on the failure of grafting procedures and/or on peri‐implanti‐
tis. Thus, the aim of the current review was to systematically assess 
the literature and perform a meta‐analysis when possible, to answer 
the following focused question: “In patients with systemic intake of 
ARDs, what is the outcome of implant therapy in terms of rates of 
implant loss, failure of grafting procedures, peri‐implant marginal 
bone levels/loss, MRONJ, and/or peri‐implantitis compared to pa‐
tients without systemic intake of ARDs?”
2  | MATERIAL AND METHODS
2.1 | Protocol and eligibility criteria
The present systematic review was performed following the criteria 
of the Preferred Reporting Items for Systematic Reviews and Meta‐
analyses (PRISMA; Liberati et al., 2009; Moher, Liberati, Tetzlaff, & 
Altman, 2009). The literature was systematically searched for origi‐
nal studies fulfilling the following inclusion criteria: (a) English or 
German language; (b) case series, cohort studies, case–control stud‐
ies, and controlled and/or randomized controlled clinical trials (CTs/
RCTs); (c) retro‐ or prospective design; (d) ≥10 patients with systemic 
intake of ARDs; (e) clearly reported relevant clinical data (please see 
data extraction section); and (f) full text available. Studies were ex‐
cluded if (a) not meeting all inclusion criteria; or (b) local application 
of ARDs.
2.2 | Information sources and literature search
Electronic search was performed in Medline (PubMed), EMBASE 
(Ovid), and CENTRAL (Ovid)—last search 05/09/2017 and no date 
restriction used, using relevant search terms (see Appendix 1). 
Additionally, screening of the reference lists of previous reviews and 
included full texts and forward search via Science Citation Index of 
included papers were conducted.
2.3 | Data collection and extraction
Two authors (KB, AS) independently checked title, abstract, and 
finally full text on the predefined eligibility criteria. Studies with 
abstracts with unclear methodology were included in full‐text as‐
sessment to avoid exclusion of potentially relevant articles. One 
author (KB) repeated the literature search. In case of ambiguity, con‐
sensus through discussion was achieved regarding the final selection 
of studies to be included.
From the included studies, one author (KB) extracted twice the 
following data when available: (a) study design; (b) no. of cases (i.e., 
patients with ARD intake) and—when available—controls (i.e., sub‐
jects without ARD intake), implants, and grafting procedures; (c) 
patient characteristics (i.e., systemic diseases/comorbidities, other 
relevant medication intake, age, gender, and smoking status); (d) in‐
dication for ARD intake, type, and administration details; (e) implant 
follow‐up time; (f) reported outcome parameters (i.e., implant loss, 
grafting procedure complication/failure, peri‐implant marginal bone 
levels/loss, MRONJ, and peri‐implantitis); and (g) MRONJ details 
(i.e., localization, attributable triggering factor, and time between 
medication intake or triggering factor and MRONJ development).
2.4 | Synthesis of results—Statistics
Implant loss was defined as the primary outcome parameter; failure 
of the grafting procedure (i.e., additional need for grafting or pre‐
cluding implant installation), marginal bone loss, MRONJ, and peri‐
implantitis were defined as secondary outcome parameters.
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Random‐effects meta‐analyses, separately for each ARD type, 
were implemented to calculate from the included cohort and case–
control studies pooled estimates at the patient and/or implant level. 




Two authors (KB and AS) independently evaluated the methodologi‐
cal and reporting quality of the included studies applying Newcastle‐
Ottawa‐Scale (NOS; Wells et al., 2016), however, with some of the 
original items modified/adapted to fit the research question herein 
as follows: (1) selection: (a) selection of controls/nonexposed cohort 
was awarded with a star, if the controls have been derived from the 
same office and (b) the item “outcome of interest was not present 
at start of study” for cohort studies was discarded, as the outcome 
of interest to include studies in the present review was “implant 
loss”; (2) comparability: smoking status and/or any augmentation 
procedure were judged as the most relevant parameters; and (3) 
exposure: (a) regarding adequate length of follow‐up, if ARD intake 
started prior to implant installation, then for long‐term outcomes 
(e.g., late implant loss), ≥5 years was required, while ≤1 year after 
prosthetic restoration was accepted for short‐term outcomes (e.g., 
early implant loss); if implant installation occurred before ARD in‐
take, then ≥3 years follow‐up since start of intake was required; (b) 
the item “nonresponse rate” was not judged for case–control studies 
if the data were based on medical records only; and (c) the item “ad‐
equacy of follow‐up of cohorts” was not judged for retrospective or 
cross‐sectional cohort studies. Thus, studies could herein achieve a 
maximum of 8 or 9 stars; for reasons of comparability, a percentage 
of awarded stars out of the possible maximum number of stars for 
each specific study was calculated. Further, the percentage of posi‐
tive scored studies for each specific item was calculated. In case of 
ambiguity, consensus through discussion was achieved.
2.5.2 | Basic reporting items in Drugs and Implants
A purpose‐made tool containing a list of items considered as neces‐
sary for meaningful reporting of ARD studies in oral implantology 
was constructed, and studies were assessed for quality of report‐
ing. Three dimensions were defined (a) subject‐, (b) medication‐, and 
(c) intervention‐related; the various items in each dimension were 
adapted to each specific ARD group (Appendix 2). Reporting of the 
various items was judged separately for each cohort of cases and 
controls, as well as for the cohorts of cases and controls presenting 
with a complication/event (i.e., implant loss, grafting procedure com‐
plication/failure, peri‐implant marginal bone levels/loss, MRONJ, 
and peri‐implantitis). The frequency of reported items per study/
cohort as percentage of the total number of items, as well as the 




Appendix 3 presents the flowchart of the literature search. Out of 
4,093 originally identified studies, 3,815 were excluded based on 
the title and 221 based on the abstract. Three records from for‐
ward search via the Science Citation Index and no records from 
reference lists of previous reviews or later included full texts were 
additionally identified; thus, 60 articles were selected for full‐
text review. Twenty‐four articles were excluded for various rea‐
sons (Appendix 4); finally, 36 articles were included. The included 
studies were grouped into “studies on BP intake” (n = 24; Table 1) 
(Al‐Sabbagh, Robinson, Romanos, & Thomas, 2015; Al‐Sabbagh, 
Thomas, Bhavsar, & De Leeuw, 2015; Bell & Bell, 2008; Bell, Diehl, 
Bell, & Bell, 2011; Famili, Quigley, & Mosher, 2011; Fugazzotto, 
Lightfoot, Jaffin, & Kumar, 2007; Goss, Bartold, Sambrook, & 
Hawker, 2010; Grant, Amenedo, Freeman, & Kraut, 2008; Jeffcoat, 
2006; Kasai, Pogrel, & Hossaini, 2009; Khoury & Hidajat, 2016; 
Koka, Babu, & Norell, 2010; Martin et al., 2010; Memon, Weltman, 
& Katancik, 2012; Mozzati et al., 2015; Shabestari et al., 2010; 
Siebert, Jurkovic, Statelova, & Strecha, 2015; Suvarna et al., 2016; 
Tallarico, Canullo, Xhanari, & Meloni, 2016; Wagenberg & Froum, 
2006; Wagenberg, Froum, & Eckert, 2013; Yajima, Munakata, 
Fuchigami, Sanda, & Kasugai, 2017; Yip, Borrell, Cho, Francisco, 
& Tarnow, 2012; Zahid, Wang, & Cohen, 2011), “studies on HRT 
intake” (n = 7; Table 2) (August, Chung, Chang, & Glowacki, 2001; 
Koka et al., 2010; Koszuta, Grafka, Koszuta, Łopucki, & Szymańska, 
2015; Minsk & Polson, 1998; Moy, Medina, Shetty, & Aghaloo, 
2005; de Souza et al., 2013; Yip et al., 2012), and “studies on 
MRONJ associated with implants” (n = 7; Table 3) (Giovannacci 
et al., 2016; Holzinger et al., 2014; Jacobsen et al., 2013; Kwon 
et al., 2014; Lazarovici et al., 2010; Pogrel & Ruggiero, 2017; 
Troeltzsch et al., 2016). Two studies (Koka et al., 2010; Yip et al., 
2012) contributed with data on both BP and HRT intake, while 
two studies (Wagenberg & Froum, 2006; Wagenberg et al., 2013) 
are based on the same study population. No studies reporting on 
SERMs, calcitonin, denosumab, SrR, c‐Src, CatK, and sclerostin in‐
hibitors, fulfilling the inclusion criteria, were identified.
3.2 | Study characteristics
Tables 1‒3 present general and more detailed characteristics on (a) 
study design; (b) no. of cases and controls, implants, and grafting 
procedures; (c) patients’ characteristics (i.e., relevant systemic dis‐
eases/comorbidities or medication intake, age, gender, and smoking 
status); (d) indication for type and administration details of ARD; 
(e) implant follow‐up time; (f) reported outcome parameters (i.e., 
implant loss, grafting procedure complication/failure, peri‐implant 
marginal bone levels/loss, MRONJ, and peri‐implantitis); and (g) 
MRONJ details of included studies. Table 4 presents a summary of 
studies reporting exact figures (numbers) on the above‐mentioned 
outcome parameters.
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3.2.1 | Studies on BP intake (n = 24)
Eight case series, 10 cohort studies, and six case–control studies re‐
porting on BP intake were included. About 2/3 of the studies were 
retrospective, six were cross‐sectional (Al‐Sabbagh, Robinson, et al., 
2015; Al‐Sabbagh, Thomas, et al., 2015; Bell & Bell, 2008; Grant et al., 
2008; Martin et al., 2010; Shabestari et al., 2010), and most were 
based only on information in the medical/dental patient journals; 
only three prospective studies (Jeffcoat, 2006; Siebert et al., 2015; 
Tallarico et al., 2016) were identified. Among studies, cases (i.e., pa‐
tients with BP intake) with implants ranged from 11 to approximately 
800, while the implant number ranged from 24 to 1267 implants; 
controls (i.e., patients without BP intake) with implants ranged from 
12 to approximately 16,000, and the implant number ranged from 28 
to approximately 28,000 implants. Two (Bell et al., 2011; Wagenberg 
et al., 2013) and five studies (Al‐Sabbagh, Robinson, et al., 2015; 
Goss et al., 2010; Martin et al., 2010; Wagenberg & Froum, 2006; 
Yip et al., 2012), respectively, did not report separately numbers of 
cases and controls on the patient or implant level. Studies report on 
an observation period ranging from 0.3 to 16 years after implant 
installation/restoration.
In six studies (Bell & Bell, 2008; Fugazzotto et al., 2007; Grant 
et al., 2008; Khoury & Hidajat, 2016; Shabestari et al., 2010; 
Suvarna et al., 2016) providing some—often nonspecific—infor‐
mation on grafting procedures in cases, the range of patients 
was 5–55 and the range of grafting sites 32–82. Five studies (Bell 
et al., 2011; Memon et al., 2012; Wagenberg & Froum, 2006; 
Wagenberg et al., 2013; Zahid et al., 2011) provided only approx‐
imate information/figures regarding grafting procedures in con‐
trols. Three studies (Memon et al., 2012; Tallarico et al., 2016; 
Wagenberg et al., 2013) reported exact figures of peri‐implant 
marginal bone loss/levels, while information on peri‐implantitis 
was rarely provided.
Collectively, some type of information was provided regarding 
implant success, failure, or loss in 23 studies, regarding grafting 
procedures in 11 studies, regarding MRONJ in 17 studies, and re‐
garding peri‐implantitis in nine studies (Table 1). More detailed sin‐
gle‐patient data on ARD type and indication for intake, as well as 
the duration of intake until MRONJ, were possible to extract from 
two studies (Al‐Sabbagh, Robinson, et al., 2015; Goss et al., 2010; 
Martin et al., 2010; Wagenberg & Froum, 2006; Yip et al., 2012) 
(six patients).
3.2.2 | Studies on HRT intake (n = 7)
Five cohort studies and two case–control studies reporting on HRT 
intake were included. All studies, but one prospective study (Koszuta 
et al., 2015), were retrospectively based on medical/dental records. 
Among studies, cases (i.e., patients with HRT intake) with implants 
ranged from 13 to 161, while the implant number ranged from 24 

























Adequate case definition 
(1)
* * 40 0
Representativeness of the 
cases (1)
* * * 60 * 100
Selection of controls (1) * * * 60 * 100
Definition of controls (1) * * * * * 100 * 100
Comparability (2)
Comparability based on 
design or analysis (2)








* * *  * * 100 * 100
Nonresponse rate (1) * x  x * 67 0
Overall % 67 63 67 75 67 67
Notes. x, the data are based on medical records, which does not allow to judge “nonresponse rate”; BP, bisphosphonate; HRT, hormone replacement 
therapy.
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to 61 implants; controls (i.e., patients without HRT intake) with im‐
plants ranged from 51 to 304, and the implant number ranged from 
379 to 661; however, four studies (Koka et al., 2010; Koszuta et al., 
2015; Moy et al., 2005; Yip et al., 2012) did not report exact implant 
numbers. Studies report on an observation period ranging from 0.3 
to 20 years after implant installation/restoration.
Two studies (August et al., 2001; de Souza et al., 2013) specifically 
excluded grafted sites, while the remaining studies did not provide 
any information on any possible grafting procedures. Collectively, 
some type of information was provided regarding implant success 
and/or loss in six studies, and on marginal bone loss in two studies 
(Table 2).
3.2.3 | Studies on MRONJ associated with implants 
(n = 7)
Among seven case series studies, reporting on MRONJ associated 
with implants, cases ranged from 11 to 27 patients (116 in total) 
and the implant number ranged from 8 to 61 implants. More de‐
tailed single‐patient data on ARD type and indication for intake, 
as well as the duration of intake until MRONJ, were possible to 
extract from four studies (68 patients) (Giovannacci et al., 2016; 
Holzinger et al., 2014; Jacobsen et al., 2013; Kwon et al., 2014; 




Tables 5 and 6 present the methodological and reporting quality as‐
sessment, based on the modified NOS, of the included case–control 
and cohort studies regarding both BPs and HRT, respectively. Case–
control and cohort studies received from 5 to 6 (i.e., 63%–75%) and 
from 1 to 6 (i.e., 14%–86%) stars, respectively. The percentage of 
positive scored studies per item ranged for BP case–control studies 
from 40% to 100% and for cohort studies from 0% to 90%, respec‐
tively; the corresponding values for HRT studies ranged from 0% 
to 100% irrespective study type. One study (Yip et al., 2012) was 
excluded from the quality assessment due to its study design not al‐
lowing comparison of cases with ARD intake versus controls; specifi‐
cally, the study compared patients with implant losses with patients 
with no losses.
3.3.2 | Basic reporting items in Drugs and Implants
Tables 7‒9 present assessment of BP, HRT, and MRONJ studies in 
terms of quality of reporting on the defined basic items. Large varia‐
tion was observed regarding the percentage of positive scored items 
among BP studies for both cases and controls, with or without com‐
plications (i.e., 0%–88%). Additionally, the percentage of positive 
scored items among the various cohorts of cases and controls, with 
or without a complication/event, was in general low; for example, 
the percentage of positive scored items in the cohort of cases with 
and without complications was ≤50% in 71% and 41% of the studies, 
respectively. Only five (i.e., gender, indication for BP intake, BP type, 
BP administration route, and time point of first BP intake) of 16 items 
were reported adequately in >50% of the studies. For example, in 
about 30% of the studies, the indication and/or administration route 
for BP intake was not clearly/precisely reported, while only 50% 
of the studies provided some information regarding smoking hab‐
its. Information on other relevant systemic diseases (e.g., diabetes) 
or medication intake (e.g., corticosteroids) was provided in only ca. 
35% of the studies. Further, about 30% of the studies did not report 
whether implants were placed before or after BP intake, while 70% 
of the studies did not include information on whether implants were 
placed in augmented or pristine bone.
Similarly, large variation was observed regarding the percent‐
age of positive scored items among HRT studies for both cases and 
controls, with or without complications (i.e., 0%–78%). Further, the 
percentage of positive scored items among the various cohorts of 
cases and controls, with or without a complication/event, was in 
general low; for example, the percentage of positive scored items 
in the cohort of cases, with and without complications, was ≤50% 
in 86% and 71% of the studies, respectively. Only three (i.e., gen‐
der, product details, and time point of first HRT intake) of 15 items 
were reported adequately in >50% of the studies. For example, 
only about 30% of the studies provided some information regard‐
ing smoking habits, other relevant systemic diseases or medication 
intake, or whether implants were placed in augmented or pristine 
bone.
Slightly better reporting, comparing to BP and HRT studies, was 
observed in the MRONJ studies regarding the patient‐ and medica‐
tion‐related items, but there was also lack of relevant information on 
intervention‐related items. The percentage of positive scored items 
ranged among studies from 0% to 100%. Further, in three of seven 
studies, the percentage of positive scored items was ≤50%, while 
nine of 16 items were reported adequately in >50% of the studies.
3.4 | Summary of results
3.4.1 | Studies on BP intake
In the majority of studies, oral BP was prescribed for osteoporosis 
treatment; only two studies (Khoury & Hidajat, 2016; Siebert et al., 
2015) reported iv administration of BP, but no study reported BP 
administration related to malignancies. In general, no significant dif‐
ferences were observed regarding implant loss between cases and 
controls, and implant success rate ranged for cases from 85.7% to 
100%, which was similar to the 84.6% to 100% of the controls; how‐
ever, the success criteria used in the various studies were rather 
different and/or questionable. In two studies, conflicting results re‐
garding implant loss were presented, with one study (Yip et al., 2012) 
reporting an odds ratio (OR) of 2.7 for BP intake compared with 
controls, while the other study (Al‐Sabbagh, Robinson, et al., 2015) 
reported an OR of 9.2 for controls (i.e., controls had a higher risk for 
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TA B L E  7   Frequency of basic reporting items among studies reporting on the effect of bisphosphonate intake on implant and/or grafting  






















time (range and 
mean) until end of 













until end of study 




I Cohort—BP intake − + + + − − + − + + + − − − − + 50
II Cohort—Non‐BP intake − + + x − − x x x x x x − − − + 33
IV Individ. with complica‐
tions (Non‐BP cohort)
− + − x − − x x x x x x − − − + 22
Wagenberg and Froum (2006)a
I Cohort – BP intake − − − + − − + − − − − − − − + − 19
II Cohort – Non‐BP intake − − − x − − x x x x x x − − + − 11
IV Individ. with complica‐
tions (Non‐BP cohort)
− + + x − − x x x x x x + − + − 44
Fugazzotto et al. (2007)a,b
I Cohort—BP intake − + − − + − + + + + + − − + + − 56
Bell and Bell (2008)b
I Cohort—BP intake − + − + − − + − + + − − − + − + 44
III Individ. with complica‐
tions (BP cohort)
− + + + − − − − + + + − + + − + 56
Grant et al. (2008)
I Cohort—BP intake + + − − + + + − + + − − − + − − 50
II Cohort—Non‐BP intake − + − x − − x x x x x x − − − − 11
III Individ. with complica‐
tions (BP cohort)
− + − − − − − − + + + − + + − + 44
IV Individ. with complica‐
tions (Non‐BP cohort)
− + − x − − x x x x x x − − − − 11
Kasai et al. (2009)
I Cohort—BP intake − + + + − − + − + + − − − − + + 50
II Cohort—Non‐BP intake − + + x − − x x x x x x − − + − 33
III Individ. with complica‐
tions (BP cohort)
− + + + − − + − + + − − + − + + 56
IV Individ. with complica‐
tions (Non‐BP cohort)
− + + x − − x x x x x x − − + − 33
Goss et al. (2010)
I Cohort—BP intake − − − − − − − − − − − − − − − − 0
II Cohort—Non‐BP intake − − − x − − x x x x x x − − − − 0
III Individ. with complica‐
tions (BP cohort)
+ + − + + + + − + + + − + + − − 69
IV Individ. with complica‐
tions (Non‐BP cohort)
− − − x − − x x x x x x − − − − 0
Koka et al. (2010)
I Cohort—BP intake + + + + + + − − − + − + − − − − 50
II Cohort—Non‐BP intake + + + x + + x x x x x x − − − − 56
III Individ. with complica‐
tions (BP cohort)
+ + + + + + + + + + + + − − − − 75
IV Individ. with complica‐
tions (Non‐BP cohort)
+ + + x + + x x x x x x − − − − 56
Martin et al. (2010)b
I Cohort—BP intake − − − − − − + − + + − − − − − − 19
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mean) until end of 













until end of study 




I Cohort—BP intake − + + + − − + − + + + − − − − + 50
II Cohort—Non‐BP intake − + + x − − x x x x x x − − − + 33
IV Individ. with complica‐
tions (Non‐BP cohort)
− + − x − − x x x x x x − − − + 22
Wagenberg and Froum (2006)a
I Cohort – BP intake − − − + − − + − − − − − − − + − 19
II Cohort – Non‐BP intake − − − x − − x x x x x x − − + − 11
IV Individ. with complica‐
tions (Non‐BP cohort)
− + + x − − x x x x x x + − + − 44
Fugazzotto et al. (2007)a,b
I Cohort—BP intake − + − − + − + + + + + − − + + − 56
Bell and Bell (2008)b
I Cohort—BP intake − + − + − − + − + + − − − + − + 44
III Individ. with complica‐
tions (BP cohort)
− + + + − − − − + + + − + + − + 56
Grant et al. (2008)
I Cohort—BP intake + + − − + + + − + + − − − + − − 50
II Cohort—Non‐BP intake − + − x − − x x x x x x − − − − 11
III Individ. with complica‐
tions (BP cohort)
− + − − − − − − + + + − + + − + 44
IV Individ. with complica‐
tions (Non‐BP cohort)
− + − x − − x x x x x x − − − − 11
Kasai et al. (2009)
I Cohort—BP intake − + + + − − + − + + − − − − + + 50
II Cohort—Non‐BP intake − + + x − − x x x x x x − − + − 33
III Individ. with complica‐
tions (BP cohort)
− + + + − − + − + + − − + − + + 56
IV Individ. with complica‐
tions (Non‐BP cohort)
− + + x − − x x x x x x − − + − 33
Goss et al. (2010)
I Cohort—BP intake − − − − − − − − − − − − − − − − 0
II Cohort—Non‐BP intake − − − x − − x x x x x x − − − − 0
III Individ. with complica‐
tions (BP cohort)
+ + − + + + + − + + + − + + − − 69
IV Individ. with complica‐
tions (Non‐BP cohort)
− − − x − − x x x x x x − − − − 0
Koka et al. (2010)
I Cohort—BP intake + + + + + + − − − + − + − − − − 50
II Cohort—Non‐BP intake + + + x + + x x x x x x − − − − 56
III Individ. with complica‐
tions (BP cohort)
+ + + + + + + + + + + + − − − − 75
IV Individ. with complica‐
tions (Non‐BP cohort)
+ + + x + + x x x x x x − − − − 56
Martin et al. (2010)b
I Cohort—BP intake − − − − − − + − + + − − − − − − 19
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mean) until end of 













until end of study 
(cohort level) or 
complication 
(individual level)
III Individ. with complica‐
tions (BP cohort)
− + + + + + + + + + + − + − − − 69
Shabestari et al. (2010)a,b
I Cohort—BP intake + + − + + − + + + + − − + + − + 69
Bell et al. (2011)a
I Cohort—BP intake − − − − − − − − − − − − − − + − 6
II Cohort—Non‐BP intake − − − x − − x x x x x x − − + − 11
IV Individ. with complica‐
tions (Non‐BP cohort)
− − + x + − x x x x x x + − + + 56
Famili et al. (2011)
I Cohort—BP intake − + − + − − + − + − − − − − − − 25
II Cohort—Non‐BP intake − + − x − − x x x x x x − − − − 11
III Individ. with complica‐
tions (BP cohort)
− + − + − − − − + + − − − − − + 31
IV Individ. with complica‐
tions (Non‐BP cohort)
− + − x − − x x x x x x − − − − 11
Zahid et al. (2011)
I Cohort—BP intake − + + + − − + − − + − − + − + + 50
II Cohort—Non‐BP intake − − − x − − x x x x x x − − + − 11
III Individ. with complica‐
tions (BP cohort)
+ + − + − − + + − + − − + − + + 56
IV Individ. with complica‐
tions (Non‐BP cohort)
− − − x − − x x x x x x − − + − 11
Memon et al. (2012)
I Cohort—BP intake + + + + + − + − + + − − + − − + 63
II Cohort—Non‐BP intake + + + x + − x x x x x x + − − + 67
III Individ. with complica‐
tions (BP cohort)
− + − + − − + − + + − − − − − + 38
IV Individ. with complica‐
tions (Non‐BP cohort)
− + − x − − x x x x x x − − − + 22
Wagenberg et al. (2013)
I Cohort—BP intake − − − + − − + − − − − − − − + − 19
II Cohort—Non‐BP intake − − − x − − x x x x x x − − + − 11
III Individ. with complica‐
tions (BP cohort)
− − − + − − + − − − − − − − + − 19
IV Individ. with complica‐
tions (Non‐BP cohort)
− − − x − − x x x x x x − − + − 11
Yip et al. (2012)
I Cohort—BP intake − + − + − − + − + − − − − − − − 25
II Cohort—Non‐BP intake − + − x − − x x x x x x − − − − 11
III Individ. with complica‐
tions (BP cohort)
− + − + − − − − + − − − − − − − 19
IV Individ. with complica‐
tions (Non‐BP cohort)
− + − x − − x x x x x x − − − − 11
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until end of study 
(cohort level) or 
complication 
(individual level)
III Individ. with complica‐
tions (BP cohort)
− + + + + + + + + + + − + − − − 69
Shabestari et al. (2010)a,b
I Cohort—BP intake + + − + + − + + + + − − + + − + 69
Bell et al. (2011)a
I Cohort—BP intake − − − − − − − − − − − − − − + − 6
II Cohort—Non‐BP intake − − − x − − x x x x x x − − + − 11
IV Individ. with complica‐
tions (Non‐BP cohort)
− − + x + − x x x x x x + − + + 56
Famili et al. (2011)
I Cohort—BP intake − + − + − − + − + − − − − − − − 25
II Cohort—Non‐BP intake − + − x − − x x x x x x − − − − 11
III Individ. with complica‐
tions (BP cohort)
− + − + − − − − + + − − − − − + 31
IV Individ. with complica‐
tions (Non‐BP cohort)
− + − x − − x x x x x x − − − − 11
Zahid et al. (2011)
I Cohort—BP intake − + + + − − + − − + − − + − + + 50
II Cohort—Non‐BP intake − − − x − − x x x x x x − − + − 11
III Individ. with complica‐
tions (BP cohort)
+ + − + − − + + − + − − + − + + 56
IV Individ. with complica‐
tions (Non‐BP cohort)
− − − x − − x x x x x x − − + − 11
Memon et al. (2012)
I Cohort—BP intake + + + + + − + − + + − − + − − + 63
II Cohort—Non‐BP intake + + + x + − x x x x x x + − − + 67
III Individ. with complica‐
tions (BP cohort)
− + − + − − + − + + − − − − − + 38
IV Individ. with complica‐
tions (Non‐BP cohort)
− + − x − − x x x x x x − − − + 22
Wagenberg et al. (2013)
I Cohort—BP intake − − − + − − + − − − − − − − + − 19
II Cohort—Non‐BP intake − − − x − − x x x x x x − − + − 11
III Individ. with complica‐
tions (BP cohort)
− − − + − − + − − − − − − − + − 19
IV Individ. with complica‐
tions (Non‐BP cohort)
− − − x − − x x x x x x − − + − 11
Yip et al. (2012)
I Cohort—BP intake − + − + − − + − + − − − − − − − 25
II Cohort—Non‐BP intake − + − x − − x x x x x x − − − − 11
III Individ. with complica‐
tions (BP cohort)
− + − + − − − − + − − − − − − − 19
IV Individ. with complica‐
tions (Non‐BP cohort)
− + − x − − x x x x x x − − − − 11
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until end of study 
(cohort level) or 
complication 
(individual level)
Al‐Sabbagh, Thomas, et al. (2015)
I Cohort—BP intake − − − − − − − − − − − − − − − − 0
II Cohort—Non‐BP intake − − − x − − x x x x x x − − − − 0
III Individ. with complica‐
tions (BP cohort)
− − − − − − − − − − − − − − − − 0
IV Individ. with complica‐
tions (Non‐BP cohort)
− − − x − − x x x x x x − − − − 0
Al‐Sabbagh, Robinson, et al. (2015)a
I Cohort—BP intake − + + + − − − − + − − − − − − − 25
II Cohort—Non‐BP intake − + − x − − x x x x x x − − − − 11
Mozzati et al. (2015)b
I Cohort—BP intake + + + + + + + − + + + − − + + − 75
III Individ. with complica‐
tions (BP cohort)
+ + + + + + + − + + + − + + + + 88
Siebert et al. (2015)a
I Cohort—BP intake − + + + + + + + + + − − + − + + 75
II Cohort—Non‐BP intake − + + x + + x x x x x x + − + + 78
Khoury & Hidajat (2016)b
I Cohort—BP intake − + + + + + + + + + + − + + + ‐ 81
III Individ. with complica‐
tions (BP cohort)
− + + + + + + + + + + − + + + + 88
Suvarna et al. (2016)b
I Cohort—BP intake − + − − − − + − − + − − − + − ‐ 25
III Individ. with complica‐
tions (BP cohort)
− + + − − − − − − + − − − + − + 31
Tallarico et al. (2016)b
I Cohort—BP intake + + + + − − + + + + − + − − + + 69
III Individ. with complica‐
tions (BP cohort)
− + + + − − + + + + − + − − + + 63
Yajima et al. (2017)a
I Cohort—BP intake − + + + + + + − + + − − − − − + 50
II Cohort—Non‐BP intake + + + x + + x x x x x x − − − + 67
III Individ. with complica‐
tions (BP cohort)
+ + + + + + + − + + + − + − − − 69
Overall %
I Cohort—BP intake 25 75 46 71 38 25 79 21 67 67 17 8 21 29 42 33
II Cohort—Non‐BP intake 19 63 38 − 25 19 − − − − − − 13 0 38 25
III Individ. with complica‐
tions (BP cohort)
29 88 47 82 35 35 65 29 77 82 47 12 53 35 35 59
IV Individ. with complica‐
tions (Non‐BP cohort)
8 62 31 − 15 8 − − − − − − 15 0 38 23
Notes. x, does not apply to this group; BP, bisphosphonate; iv, intravenous.
aNo major complication in either the BP or non‐BP group or in both—individual report not possible. bCase series—only patients with BP intake.
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Al‐Sabbagh, Thomas, et al. (2015)
I Cohort—BP intake − − − − − − − − − − − − − − − − 0
II Cohort—Non‐BP intake − − − x − − x x x x x x − − − − 0
III Individ. with complica‐
tions (BP cohort)
− − − − − − − − − − − − − − − − 0
IV Individ. with complica‐
tions (Non‐BP cohort)
− − − x − − x x x x x x − − − − 0
Al‐Sabbagh, Robinson, et al. (2015)a
I Cohort—BP intake − + + + − − − − + − − − − − − − 25
II Cohort—Non‐BP intake − + − x − − x x x x x x − − − − 11
Mozzati et al. (2015)b
I Cohort—BP intake + + + + + + + − + + + − − + + − 75
III Individ. with complica‐
tions (BP cohort)
+ + + + + + + − + + + − + + + + 88
Siebert et al. (2015)a
I Cohort—BP intake − + + + + + + + + + − − + − + + 75
II Cohort—Non‐BP intake − + + x + + x x x x x x + − + + 78
Khoury & Hidajat (2016)b
I Cohort—BP intake − + + + + + + + + + + − + + + ‐ 81
III Individ. with complica‐
tions (BP cohort)
− + + + + + + + + + + − + + + + 88
Suvarna et al. (2016)b
I Cohort—BP intake − + − − − − + − − + − − − + − ‐ 25
III Individ. with complica‐
tions (BP cohort)
− + + − − − − − − + − − − + − + 31
Tallarico et al. (2016)b
I Cohort—BP intake + + + + − − + + + + − + − − + + 69
III Individ. with complica‐
tions (BP cohort)
− + + + − − + + + + − + − − + + 63
Yajima et al. (2017)a
I Cohort—BP intake − + + + + + + − + + − − − − − + 50
II Cohort—Non‐BP intake + + + x + + x x x x x x − − − + 67
III Individ. with complica‐
tions (BP cohort)
+ + + + + + + − + + + − + − − − 69
Overall %
I Cohort—BP intake 25 75 46 71 38 25 79 21 67 67 17 8 21 29 42 33
II Cohort—Non‐BP intake 19 63 38 − 25 19 − − − − − − 13 0 38 25
III Individ. with complica‐
tions (BP cohort)
29 88 47 82 35 35 65 29 77 82 47 12 53 35 35 59
IV Individ. with complica‐
tions (Non‐BP cohort)
8 62 31 − 15 8 − − − − − − 15 0 38 23
Notes. x, does not apply to this group; BP, bisphosphonate; iv, intravenous.
aNo major complication in either the BP or non‐BP group or in both—individual report not possible. bCase series—only patients with BP intake.
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Administration route  
(i.e., oral or  
transdermal)
First intake prior to/
after surgery
Medication intake 
time (range and 
mean) until end of 
study (cohort level) 
or complication 
(individual level)
















Minsk and Polson (1998)
I Cohort—HRT intake − + + − + + − − + − − − − − − 33
II Cohort—Non‐HRT intake − + + x + + x x x x x − − − − 44
III Individ. with complica‐
tions (HRT cohort)
− + + − + + − − + − − − − − + 40
IV Individ. with complica‐
tions (Non‐HRT cohort)
− + + x + + x x x x x − − − + 56
August et al. (2001)
I Cohort—HRT intake + + + + + + + − + − − − + − + 67
II Cohort—Non‐HRT intake + + + x + + x x x x x − + − + 78
III Individ. with complica‐
tions (HRT cohort)
− + + + + + + − + − − − + − + 60
IV Individ. with complica‐
tions (Non‐HRT cohort)
− + + x + + x x x x x − + − + 67
Moy et al. (2005)
I Cohort—HRT intake − − − − − − + − + − − − − − − 13
II Cohort—Non‐HRT intake − − − x − − x x x x x − − − − 0
III Individ. with complica‐
tions (HRT cohort)
− − − − − − + − + − − − − − − 13
IV Individ. with complica‐
tions (Non‐HRT cohort)
− − − x − − x x x x x − − − − 0
Koka et al. (2010)a
I Cohort—HRT intake − + − + − − + − + − − − − − − 27
II Cohort—Non‐HRT intake − + − x − − x x x x x − − − − 11
III Individ. with complica‐
tions (HRT cohort)
+ + + + + + + − + − − − − − − 53
de Souza et al. (2013)
I Cohort—HRT intake − − − − − − − − + − − − + − − 13
II Cohort—Non‐HRT intake − − − x − − x x x x x − + − − 11
III Individ. with complica‐
tions (HRT cohort)
− − − − − − − − + − − − + − − 13
IV Individ. with complica‐
tions (Non‐HRT cohort)
− − − x − − x x x x x − + − − 11
Yip et al. (2012)
I Cohort—HRT intake − + − − − − − − − − − − − − − 7
II Cohort—Non‐HRT intake − + − x − − x x x x x − − − − 11
III Individ. with complica‐
tions (HRT cohort)
− + − − − − − − − − − − − − − 7
IV Individ. with complica‐
tions (Non‐HRT cohort)
− + − x − − x x x x x − − − − 11
Koszuta et al. (2015)
I Cohort—HRT intake − + − − − − + − + − − − − − + 27
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Minsk and Polson (1998)
I Cohort—HRT intake − + + − + + − − + − − − − − − 33
II Cohort—Non‐HRT intake − + + x + + x x x x x − − − − 44
III Individ. with complica‐
tions (HRT cohort)
− + + − + + − − + − − − − − + 40
IV Individ. with complica‐
tions (Non‐HRT cohort)
− + + x + + x x x x x − − − + 56
August et al. (2001)
I Cohort—HRT intake + + + + + + + − + − − − + − + 67
II Cohort—Non‐HRT intake + + + x + + x x x x x − + − + 78
III Individ. with complica‐
tions (HRT cohort)
− + + + + + + − + − − − + − + 60
IV Individ. with complica‐
tions (Non‐HRT cohort)
− + + x + + x x x x x − + − + 67
Moy et al. (2005)
I Cohort—HRT intake − − − − − − + − + − − − − − − 13
II Cohort—Non‐HRT intake − − − x − − x x x x x − − − − 0
III Individ. with complica‐
tions (HRT cohort)
− − − − − − + − + − − − − − − 13
IV Individ. with complica‐
tions (Non‐HRT cohort)
− − − x − − x x x x x − − − − 0
Koka et al. (2010)a
I Cohort—HRT intake − + − + − − + − + − − − − − − 27
II Cohort—Non‐HRT intake − + − x − − x x x x x − − − − 11
III Individ. with complica‐
tions (HRT cohort)
+ + + + + + + − + − − − − − − 53
de Souza et al. (2013)
I Cohort—HRT intake − − − − − − − − + − − − + − − 13
II Cohort—Non‐HRT intake − − − x − − x x x x x − + − − 11
III Individ. with complica‐
tions (HRT cohort)
− − − − − − − − + − − − + − − 13
IV Individ. with complica‐
tions (Non‐HRT cohort)
− − − x − − x x x x x − + − − 11
Yip et al. (2012)
I Cohort—HRT intake − + − − − − − − − − − − − − − 7
II Cohort—Non‐HRT intake − + − x − − x x x x x − − − − 11
III Individ. with complica‐
tions (HRT cohort)
− + − − − − − − − − − − − − − 7
IV Individ. with complica‐
tions (Non‐HRT cohort)
− + − x − − x x x x x − − − − 11
Koszuta et al. (2015)
I Cohort—HRT intake − + − − − − + − + − − − − − + 27
(Continues)
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implant loss than cases). More implant losses occurred in the poste‐
rior maxilla and mostly after a short time from installation. In general, 
no relevant differences are described between cases and controls in 
the various studies regarding peri‐implant marginal bone loss/levels, 
except for one study (Zahid et al., 2011), where an OR of was re‐
ported 3.3 for “thread exposure” in cases compared with controls.
Several studies reported no MRONJ in association with implants 
or with grafting procedures. Further, in one study (Goss et al., 2010) 
reporting on ca. 16,000 patients, only five cases with MRONJ in 
association with an implant were observed, while in another study 
including ca. 600 patients (Martin et al., 2010), one case with implant‐
related osteonecrosis was reported. However, information on both 
TA B L E  9   Frequency of basic reporting items among studies reporting on medication‐related osteonecrosis of the jaw associated with  



















(e.g., steroids) Type Dosage
Administration route  
(e.g., oral, iv, and both)




(range and mean) 
until complica‐
tion/MRONJ
Drug holiday at 















− + + + + + + + + + + − + − − + 75
Jacobsen et al. 
(2013)
− + − + − − + − + − − − + + − − 38
Holzinger et 
al. (2014)
+ + + + + − + + + + + + − − − + 75
Kwon et al. 
(2014)
+ + − + + + + − + + + − + − − + 69
Giovannacci 
et al. (2016)
+ + + + + + + − + + − − − − − − 56
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et al. (2016)
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II Cohort—Non‐HRT intake − + − x − − x x x x x − − − + 22
III Individ. with complica‐
tions (HRT cohort)
− + − − − − + − + − − − − − + 27
IV Individ. with complica‐
tions (Non‐HRT cohort)
− + − x − − x x x x x − − − + 22
Overall %
I Cohort—HRT intake 14 71 29 29 29 29 57 0 86 0 0 0 29 0 29
II Cohort—Non‐HRT intake 14 71 29 − 29 29 − − − − − 0 29 0 29
III Individ. with complica‐
tions (HRT cohort)
14 71 43 29 43 43 57 0 86 0 0 0 29 0 43
IV Individ. with complica‐
tions (Non‐HRT cohort)
0 83 33 − 33 33 − − − − − 0 33 0 50
Notes. x, does not apply to this group; HRT, hormone replacement therapy; iv, intravenous.
aNo major complication in either the HRT or non‐HRT group or in both—individual report not possible.
TA B L E  8   (Continued)
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studies seems based only on information in the medical/dental patient 
journals.
3.4.2 | Studies on HRT intake
Studies on HRT intake reported in general somehow higher implant 
loss rates in cases (9.1%–27.3%) compared to controls (7.4%–16.1%); 
one study (Moy et al., 2005) found a relative risk of 2.55 for cases 
versus controls. One study (Koszuta et al., 2015) reported larger 
amount of peri‐implant marginal bone loss in patients receiving HRT 
comparing to controls (25% vs. 15% of the implant length, respec‐
tively), while another study (de Souza et al., 2013) reported 43% 
vs. 29% of implants with peri‐implant marginal bone loss ≥2 mm at 
cases versus controls, respectively.
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− + − x − − x x x x x − − − + 22
Overall %
I Cohort—HRT intake 14 71 29 29 29 29 57 0 86 0 0 0 29 0 29
II Cohort—Non‐HRT intake 14 71 29 − 29 29 − − − − − 0 29 0 29
III Individ. with complica‐
tions (HRT cohort)
14 71 43 29 43 43 57 0 86 0 0 0 29 0 43
IV Individ. with complica‐
tions (Non‐HRT cohort)
0 83 33 − 33 33 − − − − − 0 33 0 50
Notes. x, does not apply to this group; HRT, hormone replacement therapy; iv, intravenous.
aNo major complication in either the HRT or non‐HRT group or in both—individual report not possible.
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3.4.3 | Studies on MRONJ associated with implants
Medication‐related osteonecrosis of the jaws development was 
associated with BP intake in all identified studies, except for one 
(Pogrel & Ruggiero, 2017), where in addition to the nine patients 
on BPs, two patients with denosumab intake were included. The 
MRONJ lesion was located in the mandible in 84 patients and in 34 
patients in the maxilla, and somehow more often in posterior regions 
of the jaws. In 15 and 5 patients, implant installation or explantation, 
respectively, was described as the trigger of MRONJ, while in 41 pa‐
tients, mere implant presence was considered as the trigger. Further, 
in 11 patients, an obvious reason could not be identified, while three 
studies (Holzinger et al., 2014; Jacobsen et al., 2013; Troeltzsch 
et al., 2016) did not report on any possible triggering factor. BP in‐
take was iv in 61 patients and orally in 44 patients, while one study 
(Pogrel & Ruggiero, 2017) did not specify administration pathway. 
ARD intake started prior to implant installation in 55 patients and 
in 21 patients after implant installation, while two studies did not 
specify intake starting time point (Jacobsen et al., 2013) or did not 
report on patient level (Troeltzsch et al., 2016). The timeframe be‐
tween implant installation and occurrence of MRONJ ranged from 0 
to 210 months, while the timeframe between first ARD intake and 
occurrence of MRONJ ranged from 1 to 223 months.
3.5 | Synthesis of results
Meta‐analysis was possible for implant loss, on the patient and im‐
plant level, for both BP and HRT studies (Figures 1 and 2). Based on 
four studies reporting on the patient level and eight studies report‐
ing on the implant level, no significant differences were observed in 
terms of implant loss between cases and controls in BPs studies. In 
contrast, based on two studies, HRT appeared to exert a marginally 
significant negative effect regarding implant survival on the patient 
level; however, based on another two studies, no negative effect of 
HRT was observed on the implant level.
Based on six studies reporting single‐patient data, MRONJ in 
patients on BP for osteoporosis appeared mainly >36 months after 
start of drug intake (in 29 of 41 patients; 71%), while in patients with 
cancer, MRONJ appeared mainly ≤36 months after BP intake (20 out 
of 32 patients; 64%) (Figure 3).
4  | DISCUSSION
A considerable portion of the adult population (estimated to about 
15% for persons ≥ 50 years of age) is suffering from osteoporosis 
and has received and/or is receiving treatment with ARDs, mainly 
BPs and denosumab; these drugs are also used for the management 
of other conditions, such as primary or metastatic malignancies of 
the bones. ARDs have traditionally been divided according to the 
route of administration (i.e., oral, sc, and iv). Current understanding, 
however, is that dose rather than route of administration per se is im‐
portant; thus, low‐ and high‐dose ARDs can be today administered 
through all three routes (Table 10). Primarily, low dose is used for 
osteoporosis treatment, whereas high dose is used in patients with 
F I G U R E  1   Forest plot from random‐effects meta‐analyses of 
the included cohort and case–control studies on bisphosphonates 
presenting pooled estimates at the patient (PL) and implant level (IL)
F I G U R E  2   Forest plot from random‐effects meta‐analyses 
of the included cohort and case–control studies on hormone 
replacement therapy presenting pooled estimates at the patient 
(PL) and implant level (IL)
F I G U R E  3   Bar chart showing the number of cases of 
medication‐related osteonecrosis of the jaws at different 
timeframes in patients with low‐ and high‐dose bisphosphonate 
intake, based on single‐patient data reported in six studies
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cancer with bone metastases. In this context, it is relevant to assess 
possible side effects of ARD intake in connection to various aspects 
of implant therapy, including fixture installation, bone augmentation 
interventions, and late biological complications.
It is recognized that OCL‐mediated bone resorption plays major 
role during various stages of morphogenesis of dental implant 
osseointegration and during peri‐implant bone homeostasis. For 
example, during the early weeks postinstallation, extensive bone 
resorption occurs at the pitches of the thread where the implant is 
engaged with the bone achieving primary anchorage, that is, at the 
points of pressure, while OCL also cleanse the bone debris within 
the peri‐implant hard tissue wound (Berglundh, Abrahamsson, 
Lang, & Lindhe, 2003). Furthermore, OCLs mediate marginal peri‐
implant bone modeling at later stages of healing to establish the 
marginal hard tissue seal around the implant and are fundamental 
for peri‐implant bone homeostasis under functional loading (e.g., 
bone microcrack repair) (Insua, Monje, Wang, & Miron, 2017; Rossi 
et al., 2014). As ARDs interfere through various mechanisms with 
bone remodeling, and primarily with OCL function, it is reasonable 
to consider that these drugs may compromise aspects of implant 
therapy; for example, more implants might fail to integrate, or 
larger peri‐implant marginal bone loss might occur during model‐
ing or functional loading, or those patients may be prone to peri‐
implant infections.
Keeping in mind the fact that study design, size, and follow‐up 
time varied considerably among the identified studies, meta‐anal‐
ysis was deemed possible to perform herein regarding implant loss 
for BPs and HRT, on both the implant and patient level. The results 
showed that patients on BPs for osteoporosis treatment (i.e., low 
dose) do not lose a significantly larger number of implants compared 
with persons not taking such medications, and the number of pa‐
tients experiencing implant loss is similarly low in those patients 
compared with those without systemic BP intake. This regards both 
patients on low‐dose BP receiving implants and patients with im‐
plants that start to take low‐dose BP. These results are in accor‐
dance with what reported in other recent systematic reviews on the 
topic (Ata‐Ali, Ata‐Ali, Peñarrocha‐Oltra, & Galindo‐Moreno, 2016; 
Chrcanovic, Albrektsson, & Wennerberg, 2016; Walter, Al‐Nawas, 
Wolff, Schiegnitz, & Grötz, 2016). In very crude numbers, consider‐
ing only studies reporting exact figures and irrespective study de‐
sign, out of a total of 2,894 implants placed in patients on BPs, only 
54 were lost versus 60 implants lost out of 3946 implants placed in 
TA B L E  1 0   List of ARDs currently used for osteoporosis and cancer treatment. Updated February 2018
Trade name Generic name Diagnosis Administration route Dosing interval Dose
Fosamax Alendronate Osteoporosis Oral Weekly 70 mg
Alendronate Alendronate Osteoporosis Oral Weekly 70 mg
Fosavance Alendronate + cholecalcif‐
erol (vitamin D3)
Osteoporosis Oral Weekly 70 mg + 70 μg
Aclasta Zoledronate Osteoporosis iv Yearly 5 mg
Pamidronate sodium Pamidronate Osteoporosis iv Yearly 5 mg
Bonviva Ibandronate Osteoporosis iv Monthly 1 mg/ml
Bonviva Ibandronate Osteoporosis Oral Monthly 150 mg
Ibamyl Ibandronate Osteoporosis Oral Monthly 150 mg
Ibandronate “Stada” Ibandronate Osteoporosis Oral Monthly 150 mg
Ibandronic acid 
“medical valley”
Ibandronate Osteoporosis Oral Monthly 150 mg
Optinate Septimum Risedronate Osteoporosis Oral Weekly 35 mg
Risedronate sodium Risedronate Osteoporosis Oral Weekly 35 mg
Riseostad Risedronate Osteoporosis Oral Weekly 35 mg
Primadronat Risedronate Osteoporosis Oral Weekly 35 mg





Zoledronate Cancer iv 3–4 weeks 4 mg
Pamifos Pamidronate 
sodium “Hospira”
Pamidronate Cancer iv 3–4 weeks 90 mg
Bonefos Clodronate Cancer Oral Daily 1,600 mg
Bondronate Ibandronate Cancer iv 3–4 weeks 6 mg
Bondronate Ibandronate Cancer Oral Daily 50 mg
Xgeva Denosumab Cancer sc 4 weeks 120 mg
Notes. iv, intravenous; sc, subcutaneous injection.
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patients without BP intake (i.e., 1.9% vs. 1.5%, respectively); this cor‐
responds to 4.0% versus 6.2% of patients, respectively, experienc‐
ing implant loss. Similarly, the meta‐analysis showed that patients 
receiving HRT lose a similar number of implants as those not taking 
such medications; on the patient level, however, it appeared that sig‐
nificantly more HRT patients experienced implant loss compared to 
the non‐HRT group. Nevertheless, both meta‐analyses on HRT are 
based on only two studies each, while one of the two studies re‐
porting on patient level presented an unusually large number of pa‐
tients with implant loss in both HRT and non‐HRT groups (i.e., 27% 
vs. 16%, respectively) (Moy et al., 2005). In general, it seemed that 
the majority of reported implant losses in ARD patients occur within 
short time postinstallation/postloading (i.e., early losses), and some‐
how more often in the posterior maxilla. Similar numbers and pat‐
terns regarding implant losses have previously been reported for the 
general population (Bryant, 1998; Quirynen, Van Assche, Botticelli, 
& Berglundh, 2007). In this context, it has to be stressed that there 
are not much data available to draw conclusions on the success or 
safety of bone grafting procedures in conjunction with implant in‐
stallation in patients on ARDs, or on the possible effect of low‐dose 
sc and iv ARD administration on the outcome of implant placement 
or preexisting implants in patients with osteoporosis.
In the studies included in this review, information about peri‐im‐
plant marginal bone levels/loss was scarce; only very few studies 
reporting on BPs for osteoporosis treatment presented exact fig‐
ures (i.e., distance in mm). In particular, the possible impact of BPs on 
peri‐implant marginal bone modeling was assessed only in one study 
(Memon et al., 2012). In this study, no difference was noted between 
implants placed in patients on BPs and those placed in patients with‐
out BP intake, 4–6 months after installation at second‐stage surgery, 
with both groups exhibiting peri‐implant marginal bone levels that 
are considered as normal (0.87 vs. 0.92 mm, respectively) (Laurell & 
Lundgren, 2011). Further, only one study reported on peri‐implant 
bone levels on the long term (Wagenberg et al., 2013), with no dif‐
ferences observed between implants in patients with and without 
BP intake in terms of peri‐implant marginal bone loss 1 to 20 years 
postloading (i.e., 0.61 vs. 0.53 mm, respectively). Additionally, in 
90% of the implants, peri‐implant marginal bone loss was <1.5 mm, 
and the small number of implants (i.e., 2.5%) exhibiting a peri‐im‐
plant marginal bone loss >3 mm was not specifically associated with 
BP intake. Obviously, as these two studies evaluated bone levels at 
distinctly different time points in terms of peri‐implant bone biol‐
ogy, that is, second‐stage surgery and several years postloading, no 
meta‐analysis was performed herein regarding peri‐implant marginal 
bone levels for BP studies, although technically feasible. In the two 
studies reporting on marginal bone levels around implants placed in 
HRT vs. control patients, significantly more bone loss both during 
the osseointegration phase (Koszuta et al., 2015) and on the long 
term (de Souza et al., 2013) was observed in the HRT group; how‐
ever, the studies did not provide precise values in mm.
In this context, reduced peri‐implant marginal bone levels 
may represent a surrogate sign for peri‐implantitis. Indeed, in this 
systematic review, the literature search included terms about 
peri‐implantitis, but only a handful of publications fulfilled the in‐
clusion criteria. In particular, out of 24 and seven studies reporting 
on BP and HRT intake, respectively, only two studies on patients re‐
ceiving BPs for osteoporosis treatment reported explicitly assessing 
peri‐implantitis; specifically, the authors stated that there were no 
cases of peri‐implantitis (Khoury & Hidajat, 2016; Shabestari et al., 
2010). Nevertheless, in the latter study, a small fraction of the eval‐
uated implants (i.e., 6%) had three threads exposed, and considering 
the fact that the implants in this study were one‐piece tissue level 
implants, one may question the validity of the findings/reporting in 
this study. The concern that patients on ARDs may have a higher 
risk for peri‐implantitis should be also seen in light of MRONJ. As 
mentioned earlier, this condition has been recognized already for 
more than a decade as a side effect of BPs associated with dentoal‐
veolar procedures, but now it is accepted that similar lesions can 
occur also in patients receiving other types of ARDs (Aljohani et al., 
2017; Boquete‐Castro, Gómez‐Moreno, Calvo‐Guirado, Aguilar‐
Salvatierra, & Delgado‐Ruiz, 2016). The pathogenesis of the condi‐
tion is not completely understood and seems to be multifactorial, 
but one mechanism among others is that bone is more vulnerable 
to infection due to decreased remodeling. Thus, the presence of an 
implant could in some cases function as a locus minori resistentiae for 
the development of MRONJ; for example, plaque‐induced peri‐im‐
plantitis triggers MRONJ or microcracks develop around the loaded 
implant, do not repair timely, accumulate, and give rise to necrosis. 
Most of the articles included in the present systematic review, how‐
ever, reported no MRONJ in association with implants or grafting 
procedures. Specifically, in 16 studies on BP intake (mainly low dose 
for osteoporosis treatment), however, with variable design and fol‐
low‐up time, only one case of MRONJ of 1,390 inserted implants 
was reported, while no studies on HRT intake reported on the event 
MRONJ. On the other hand, in a few publications fulfilling the inclu‐
sion criteria of this systematic review (i.e., reporting on ≥ 10 cases), 
some relevant information on MRONJ in association with implant 
therapy was provided. About 10% of MRONJ cases occurred during 
the first year of BP intake, and in some cases, drug intake was prior 
to implant installation, while in other cases, patients started taking 
the drugs after implant placement; occasionally, MRONJ appeared 
within a short timeframe of weeks of drug intake. Mere implant 
presence was considered as the trigger for MRONJ in about 30% 
of the patients, while in about 16% of the cases, the lesion was re‐
lated to implant installation or explantation; in about 10% of the 
cases, no obvious reason for MRONJ could be identified, while in 
several of the cases, comorbidities (e.g., corticosteroid intake) were 
present. Based on single‐patient data, MRONJ associated with im‐
plants appeared to occur after a shorter period of time in patients 
with cancer on high‐dose ARD intake compared with patients with 
osteoporosis on low‐dose ARD intake. Specifically, the majority of 
MRONJ cases (71%) in patients on low‐dose BP occurred >3 years 
of drug intake, while MRONJ in patients on high‐dose BP appeared 
mainly <3 years (64% of the cases). In perspective, it is known that 
the risk of MRONJ generally increases with duration of ARD therapy 
(Kajizono et al., 2015). These observations are in accordance with 
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information presented in recent systematic reviews and position pa‐
pers on MRONJ (Aljohani et al., 2017; Ruggiero et al., 2014; Walter 
et al., 2016). Thus, the risk for MRONJ development appears to be 
multifactorial, and in general, high‐dose ARD intake for manage‐
ment of malignancies, low‐dose oral BP intake over a longer period 
of time, and presence of comorbidities (e.g., diabetes and corticoste‐
roid intake), as well as procedures involving the mandible, should be 
considered as risk factors for MRONJ also in regards with implant 
therapy. In this context, the information provided in the studies in‐
cluded herein was very limited to draw any conclusions regarding 
the potential benefits of the “drug holiday” concept (i.e., drug intake 
interruption prior to and/or during implant therapy), which has been 
recommended in published clinical guidelines (Ruggiero et al., 2014).
In this systematic review, to assess the quality of the included 
studies, an established tool (NOS) (Wells et al., 2016) and a purpose‐
made tool (Basic reporting items in Drugs and Implants [BaRIDI]) 
including a list of basic reporting patient‐, medication‐, and interven‐
tion‐related items considered relevant for a better coverage of this 
specific topic were used. In general, irrespective of the tool used, 
most of the included studies were of moderate to questionable qual‐
ity, in terms of design, number of included cases and/or controls, and 
especially reporting. For example, information on concomitant dis‐
eases or other relative interacting medications was reported in only 
about 35% of the studies. Similarly, in about 30% of the studies, the 
indication and/or administration route for BP intake was not clearly/
precisely reported, while only 50% of the studies provided some 
information regarding smoking habits. Further, about 30% of the 
studies did not report whether implants were placed before or after 
BP intake, and 70% of the studies did not include information on 
whether implants were placed in augmented or pristine bone. Most 
likely, all missing information was simply not possible to retrieve, as 
most of the studies were retrospective, a study design with inherent 
issues regarding the accuracy and completeness of information.
In perspective, the relatively limited number of studies report‐
ing on aspects of implant therapy in patients on ARDs that could 
be included herein could simply be explained by the fact that im‐
plant therapy is not compromised by ARD intake at an extent that 
it becomes an obvious problem in every day clinical work, and thus, 
there is not so much “to write home about”. It would otherwise be 
expected that many more studies—even in the form of case reports 
fulfilling the inclusion criteria (i.e., reporting on ≥ 10 cases)—would 
have been published and identified by the current systematic review, 
at least as it regards the long‐standing BPs. On the other hand, lack 
of studies may reflect the fact that clinicians are aware of the risks in 
patients with ARD intake and simply are very cautious when treating 
these patients, including use of antibiotic prophylaxis and antiseptic 
mouth rinses, or simply refrain from treating them. In this context, 
the current review used a much wider search term basis compared 
to previous systematic reviews on this topic (e.g., Ata‐Ali et al., 2016; 
Chrcanovic et al., 2016; Walter et al., 2016), both regarding implant 
therapy‐related terms and ARDs; in particular, the search strategy 
included terms related to bone augmentation procedures and peri‐
implant biological complications, as well as ARDs that have either 
been abandoned or not widely used, among other reasons due to 
systemic side effects (e.g., HRT and SrR has been associated with an 
increase in cardiovascular problems), or are still under development 
(e.g., CatK inhibitor and antisclerostin antibody) in order to obtain 
a comprehensive view of the field. It appears thus unlikely that a 
relevant number of significant publications may have been missed.
In conclusion, the results of the present systematic review 
showed
• Low‐dose oral BP intake for osteoporosis treatment, in general, 
does not compromise implant therapy, that is, these patients do 
not lose more implants nor get more implant‐related complica‐
tions/failures (i.e., in regard with grafting procedures, peri‐implant 
marginal bone loss, MRONJ, and peri‐implantitis), comparing to 
implant patients without BP intake.
• There is almost no relevant information available on the possible 
effect on implant therapy of high‐dose BPs or other widely used 
ARDs (e.g., denosumab).
• HRT has no negative effect on the implant level, while it appears 
to exert a marginally significant negative effect regarding implant 
survival on the patient level and regarding peri‐implant marginal 
bone levels.
• The available knowledge regarding success or safety of bone 
grafting procedures in conjunction with implant installation is too 
limited to draw conclusions.
• The information is derived from studies with generally low quality, 
in terms of design, number of included cases and/or controls, and 
especially reporting.
• There are valid reasons to consider as high‐risk patients for 
MRONJ those patients with high‐dose ARD intake for manage‐
ment of malignancies, patients on oral BP over a longer period 
of time, and patients with comorbidities; both implant instal‐
lation/explantation and implant presence per se may trigger 
MRONJ.
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APPENDIX 1 
Information sources and literature search
Electronic search was performed in Medline (PubMed), EMBASE (Ovid), and CENTRAL (Ovid) — last search 05/09/2017, no date restriction. 
The database Medline (PubMed) was searched with the following keywords: (dental OR oral) AND (implant therapy OR implant treatment OR 
dental implant OR dental implants OR implant OR implants OR oral implants OR osseointegration OR osseo‐integration OR implant loss OR 
implant failure OR peri‐implantitis OR periimplantitis OR peri‐implant disease OR periimplant disease OR alveolar ridge augmentation OR bone 
regeneration OR guided tissue regeneration OR bone grafting OR bone substitutes OR bone augmentation OR bone augmentations OR lateral 
bone augmentation OR lateral ridge augmentation OR guided bone regeneration OR gbr OR bone graft substitute OR bone graft substitutes 
OR autogenous bone graft OR autogenous bone grafts OR bone block OR bone blocks OR split ridge osteotomy OR split ridge osteotomies 
OR ridge expansion OR ridge expansions OR maxillary sinus OR sinus OR augmentation OR elevation OR lift* OR graft*) AND (antiresorptive 
agent OR antiresorptive agents OR anti‐resorptive agent OR anti‐resorptive agents OR antiresorptive drug OR antiresorptive drugs OR anti‐
resorptive drug OR anti‐resorptive drugs OR bisphosphonate OR bisphosphonates OR alendronate OR alendronic acid OR ibandronate OR 
Ibandronic acid OR risedronate OR risedronic acid OR zoledronate OR zoledronic acid OR pamidronate OR pamidronic acid OR etidronate OR 
etidronic acid OR clodronate OR clodronic acid OR tiludronate OR tiludronic acid OR estrogen OR estrogens OR oestrogen OR oestrogens OR 
selective estrogen receptor modulator OR selective estrogen receptor modulators OR selective estrogen‐receptor modulator OR selective 
estrogen‐receptor modulators OR selective oestrogen receptor modulator OR selective oestrogen receptor modulators OR selective oestro‐
gen‐receptor modulator OR selective oestrogen‐receptor modulators OR SERM OR SERMs OR raloxifene OR bazedoxifene OR calcitonin OR 
human monoclonal antibody to receptor activator for nuclear factor kappa B ligand OR human monoclonal antibody to RANKL OR denosumab 
OR RANK ligand OR RANKL antibody OR saracatinib OR c‐src kinase OR c‐src inhibitor OR cathepsin K OR cathepsin K inhibitor OR odana‐
catib OR romosozumab OR sclerostin antibody OR sclerostin inhibitor OR sclerostin OR strontium ranelate OR strontium). For the other two 
databases, comparable terms were used, but adapted to the specific criteria of the particular database.
APPENDIX 2 
Basic reporting items in Drugs and Implants (BaRIDI)




Reason for medication intake (e.g., osteoporosis and 
cancer)
Reported yes/no
Comorbidities (e.g., diabetes) Reported yes/no
Other relevant medications (e.g., steroids) Reported yes/no
Medication‐related Typea Reported yes/no
Dosagea Reported yes/no
Product details (i.e., content and/or dosage)b Reported yes/no
Administration route (oral, iv, or both for BP and 
MRONJ studies; oral or transdermal for HRT studies)
Reported yes/no
First intake prior to/after surgery Reported yes/no
Medication intake time until end of study (cohort level) 
or complication (individual level)
Range and mean 
reported yes/no
Drug holiday at surgery (i.e., yes/no, duration) Reported yes/no
Intervention‐related Implant—region/MRONJ—region Jaw type and anterior or 
posterior region reported 
yes/no
Augmentation/pristine Reported yes/no
Perioperative medication (e.g., antibiotics) Reported yes/no
Follow‐up period until end of study (cohort level) or 
complication (individual level)
Range and mean 
reported yes/no
aRelevant for BP and MRONJ studies. 
bRelevant for HRT studies.
Note. BP, bisphosphonate; HRT, hormone replacement therapy; iv, intravenous; MRONJ, medication‐related osteonecrosis of the jaw.
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APPENDIX 3 
Flowchart of the inclusion process of studies for the systematic review
APPENDIX 4 
Reasons for exclusion of 24 full texts
Study (year) Reason for exclusion
Stvrtecky, Kaufman, and Borgetti, (1995) Only 9 patients
Marx, Sawatari, Fortin, and Broumand (2005) Only 4 patients with MRONJ associated with implants
Phillips (2007) Review
Albandar (2008) Summary of Grant et al. (2008)
Wynn (2008) Review
Zuffetti et al. (2009) Single case report, local BP application
Kos, Kuebler, Luczak, and Engelke (2010) Only 1 patient with MRONJ associated with implants
Borromeo et al. (2011) Published study protocol
Akintoye (2012) Summary of Yip et al. (2012)
Andriani et al. (2012) Only 3 patients associated with implants
Griffiths (2012) Only 5 patients with BP intake
Jacobsen, Metzler, Obwegeser, Zemann, and Graetz (2012) No relevant data on MRONJ patients associated with implants 
Leonida, Vescovi, Baldoni, Rossi, and Lauritano (2012) Only 9 patients
Fleisher et al. (2013) Only 8 patients with MRONJ associated with implants
Holzinger et al. (2013) No relevant data on MRONJ patients associated with implants 
López‐Cedrún et al. (2013) Only 9 patients
Borromeo et al. (2014) Only 3 patients associated with implants
Taxel et al. (2014) Relevant clinical data not reported
Famili and Zavoral (2015) Only 3 patients with relevant medication intake
Nisi et al. (2015) Only 9 patients with MRONJ associated with implants
Rugani, Kirnbauer, Acham, Truschnegg, and Jakse (2015) Single case report
Matsuo et al. (2016) Only 6 patients
Gurgel et al. (2017) Patients with BP and/or HRT intake not reported separately
Wagner et al. (2017) Only 5 patients with BP intake
Note. BP, bisphosphonate; HRT, hormone replacement therapy; MRONJ, medication‐related osteonecrosis of the jaw.
